186.50
-3.50
(-1.84%)
May 20 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 186.50 - 188.00 |
| 52 week | 99.00 - 250.00 |
| Open | 190.00 |
| Vol. | 3,750.00 |
| Mkt cap | 37.60M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.41* |
| Shares | 20.16M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -205.69% | -213.17% |
| Operating margin | -201.83% | -211.93% |
| EBITD margin | - | -206.92% |
| Return on average assets | -69.68% | -67.42% |
| Return on average equity | -128.30% | -100.26% |
| Employees | 97 | - |
| Carbon Disclosure Rating | - | - |
Address
Lombard Medical House 4 Trident Park, Basil Hill Road
DIDCOT, ENG OX11 7HJ
United Kingdom - Map
+44-1235-750800 (Phone)
+44-1235-750879 (Fax)
DIDCOT, ENG OX11 7HJ
United Kingdom - Map
+44-1235-750800 (Phone)
+44-1235-750879 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Lombard Medical Technologies PLC (LMT) is a medical technology company. The Company�s principal activities are the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through its own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. LMT�s Aorfix product is the endovascular stent graft for patients with tortuous vascular anatomy. Aorfix combines a design and technology that result in clinical performance in endovascular aortic repair (EVAR) patients with complex anatomy. The product is used to treat complex aneurysms up to 90 degrees. Aorfix includes nitinol rings and a helical scaffold covered by a woven polyester fabric. LMT�s subsidiaries include Lombard Medical Limited, PolyBioMed Limited, LionMedical Limited, Lombard Medical Technologies Inc Lombard Medical Scotland Limited.
Officers and directors
| Simon Hubbert | Chief Executive Officer, Executive Director | |
| Ian Leslie Ardill | Chief Financial Officer, Company Secretary, Executive Director | |
| Peter Phillips | Chief Technology Officer, Executive Director | |
| John Barry Rush | Non-Executive Chairman of the Board | |
| Simon J. Neathercoat | Non-Executive Deputy Chairman of the Board | |
| Thomas Theodore Casdagli | Non-Executive Director | |
| Timothy Haines | Non-Executive Director | |
| Craig Robert Rennie | Non-Executive Director |